1. A pharmaceutical aerosol preparation intended for use in metered-dose inhalers (BITs), comprising (a) from 0.001 to 0.05% w / w. a pharmaceutically acceptable salt or solvate of formoterol； (b) from 0.05 to 0.16% w / w. beclomethasone dipropionate (BDP)； (c) from 2.0 to 4.8% w / w. ethanol； (d) HFA 134a characterized in that HFA 134a is the only propellant and the formoterol salt is suspended in micronized form, while the corticosteroid is completely dissolved. The preparation according to claim 1, comprising, as active ingredients, only a combination of formoterol salt and beclomethasone dipropionate. The drug according to claim 1 or 2, in which the salt of formoterol is selected from the group of fumarate, maleate, xinafoate and pamoate. The drug according to claim 3, in which the salt of formoterol is a fumarate dihydrate. The drug according to claim 1, in which the amount of ethanol is from 2.5 to 4.5% wt./wt. 6. The drug according to claim 5, in which the specified amount is from 2.5 to 4.0% wt./wt. 7. A metered-dose inhaler comprising a container filled with a pharmaceutical preparation according to any one of claims 1 to 6, and a metering valve for delivering therapeutically effective doses of the active ingredients. The metered-dose metered-dose inhaler according to claim 7, wherein the dose of formoterol salt is 6 or 12 mcg. A metered-dose inhaler according to claim 7 or 8, wherein the dose of beclomethasone dipropionate is 50 or 100 μg. Use of a corticosteroid in an aerosol inhalation preparation comprising a pharmaceutically acceptable salt or solvate of formoterol as an active ingredient and a mixture of HFA 134 and ethanol as a carrier to reduce solubility1. Фармацевтический аэрозольный препарат, предназначенный для применения в дозирующих ингаляторах под давлением (ДИД), включающий(a) от 0,001 до 0,05% мас./мас. фармацевтически приемлемой соли или сольвата формотерола；(b) от 0,05 до 0,16% мас./мас. беклометазона дипропионата (БДП)；(c) от 2,0 до 4,8%
